CA-VELODYNE-LIDAR
28.4.2020 14:02:06 CEST | Business Wire | Press release
Velodyne Lidar, Inc. today announced a three-year agreement with EasyMile, a global leader in driverless technology and smart vehicle solutions. EasyMile uses Velodyne lidar sensors in production of its EZ10 autonomous passenger shuttles that are deployed on public and private roads in more than 30 countries around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200428005241/en/
EasyMile will enhance its EZ10 shuttle fleet with Velodyne’s state-of-the-art sensors for safe and efficient navigation on roadways. Electric and driverless, the EZ10 shuttle was the one of the first autonomous shuttles launched in April 2015. It has a track record of over 200 deployments and more than 600,000 km driven in autonomous mode and one of the most advanced technology currently available. The shuttle, which has capacity for up to 15 passengers, includes a built-in automated electric ramp to support accessibility for individuals with disabilities.
“For precise navigation in real time, the EZ10s use our algorithm that fuses data from a variety of perception sensors, including lidar and camera, and localization sensors, including GPS, INS and odometry. Velodyne lidars along with radar scan for objects, vehicles, animals and people that might pose a collision threat, feeding that information to the vehicle’s control software,” explained Olivier Pairot, EasyMile’s Director of Product Marketing. “By utilizing Velodyne sensors, we are able to best gather information on every part of our environment, both close to the vehicle and at longer ranges.”
“Velodyne’s high performance lidar technology is a key component in enabling our autonomous vehicles to deliver smart mobility in urban, suburban and private environments,” said Benoit Perrin, Managing Director and COO, EasyMile. “Velodyne’s solutions have the reliability, quality and production scale we are looking for to continue to grow our fleet worldwide.”
“The EasyMile EZ10 provides a shared, inclusive driverless shuttle solution that improves public transport by connecting hubs and in many cases, delivers a transport service where there otherwise wasn’t one available,” said Erich Smidt, Executive Director Europe, Velodyne Lidar. “These shuttles show how Velodyne lidar sensors provide real-time perception data that enables safe and reliable operation for autonomous vehicles across business parks, public transport connections, university campuses and more.”
Velodyne’s sensors are optimized for outstanding indoor and outdoor performance, operating in a variety of light conditions. By combining high-resolution 3D perception with a broad vertical field of view, they can accurately detect a variety of objects.
About Velodyne Lidar
Velodyne provides smart, powerful lidar solutions for autonomy and driver assistance. Headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. Velodyne’s founder, David Hall, invented real-time surround view lidar systems in 2005 as part of Velodyne Acoustics. Mr. Hall’s invention revolutionized perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™, the versatile Ultra Puck™, the autonomy-advancing Alpha Prime™, the ADAS-optimized Velarray™, and the groundbreaking software for driver assistance, Vella™.
About EasyMile
EasyMile is a global leader in driverless technology and smart vehicle solutions. The fast-growing company develops software to automate transportation platforms without the need for dedicated infrastructure. EasyMile’s cutting-edge technology is revolutionizing passenger and goods transportation, offering new mobility options. EasyMile has already deployed close to 250 driverless projects in more than 30 countries and transported people over 600,000 km. Clients include the world’s largest transport operators, city authorities, airports, corporations, business parks, and universities. Founded in 2014, EasyMile has a global presence with headquarters in Toulouse (France) and regional offices in Denver (USA), Berlin (Germany), Adelaide (Australia) and Singapore. The Company employs over 200 highly skilled and passionate employees specializing in robotics, computer vision and vehicle dynamics. Besides the two founders, CEO Gilbert Gagnaire and Board Member Philippe Ligier, EasyMile benefits from the backing of minority shareholders and strategic partners, Alstom, Continental and Bpifrance.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200428005241/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom